Fierce Biotech
Merck's HIV combo matches Gilead's Biktarvy in latest phase 3 test for islatravir
Merck & Co. | Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval molecule as a new anchor treatment for the infectious disease.
